Chest[journal] 检索结果

341. A Prospective Randomized Controlled Trial Comparing the Efficacy and Safety of Cup vs Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis.

作者: Inderpaul Singh Sehgal.;Amanjit Bal.;Sahajal Dhooria.;Parimal Agrawal.;Nalini Gupta.;Babu Ram.;Ashutosh N Aggarwal.;Digambar Behera.;Ritesh Agarwal.
来源: Chest. 2016年149卷6期1584-6页

342. Response.

作者: Micah R Whitson.;Edwin Mo.;Lauren Healy.;Mangala Narasimhan.;Seth Koenig.;Paul H Mayo.
来源: Chest. 2016年149卷6期1583-4页

343. Considerations on Midodrine Use in Resolving Septic Shock.

作者: Drayton Adam Hammond.;Melanie N Smith.;Nikhil Meena.
来源: Chest. 2016年149卷6期1582-3页

344. Response.

作者: Gulrukh Zaidi.
来源: Chest. 2016年149卷6期1581-2页

345. Tele-Medicine and Point-of-Care Ultrasound: A New Paradigm for Resource-Constrained Settings.

作者: Andrea R Levine.;Thomas E Robertson.;Alfred Papali.;Avelino C Verceles.;Michael T McCurdy.
来源: Chest. 2016年149卷6期1580-1页

346. Response.

作者: Lisa R Young.;Timothy J Vece.;R Paul Guillerman.
来源: Chest. 2016年149卷6期1579-80页

347. Anything that Looks Like a Neuroendocrine Cell Hyperplasia of Infancy Is Not Necessarily a Neuroendocrine Cell Hyperplasia of Infancy.

作者: Laureline Berteloot.;Louise Galmiche-Rolland.;Rola Abou-Taam.
来源: Chest. 2016年149卷6期1578-9页

348. Response.

作者: Courtenay R Bruce.;Trevor Bibler.;Andrew M Childress.;Ashley L Stephens.;Adam M Pena.;Nathan G Allen.
来源: Chest. 2016年149卷6期1577-8页

349. When Patients and Surrogates Disagree About Advance Directives.

作者: Peter Terry.
来源: Chest. 2016年149卷6期1576-7页

350. Clinical Data Are Essential to Validate Lung Ultrasound.

作者: Francesco Raimondi.;Fiorella Migliaro.;Daniele De Luca.;Nadya Yousef.;Javier Rodriguez Fanjul.
来源: Chest. 2016年149卷6期1575页

351. Response.

作者: Jing Liu.
来源: Chest. 2016年149卷6期1575-6页

352. Rebuttal From Drs Coz Yataco, Flannery, and Simpson.

作者: Angel O Coz Yataco.;Alexander H Flannery.;Steven Q Simpson.
来源: Chest. 2016年149卷6期1371-2页

353. Rebuttal From Dr Caironi.

作者: Pietro Caironi.
来源: Chest. 2016年149卷6期1370-1页

354. COUNTERPOINT: Should Intravenous Albumin Be Used for Volume Resuscitation in Severe Sepsis/Septic Shock? No.

作者: Angel O Coz Yataco.;Alexander H Flannery.;Steven Q Simpson.
来源: Chest. 2016年149卷6期1368-70页

355. POINT: Should Intravenous Albumin Be Used for Volume Resuscitation in Severe Sepsis/Septic Shock? Yes.

作者: Pietro Caironi.
来源: Chest. 2016年149卷6期1365-7页

356. Longitudinal Lung Function Decrements in Firefighters Who Responded to the World Trade Center Disaster: Important Insights for the Preservation of Lung Function in Future Disasters.

作者: Lawrence C Mohr.
来源: Chest. 2016年149卷6期1362-4页

357. Are the Effects of OSA on the Cardiovascular System Reversible?

作者: Geraldo Lorenzi-Filho.;Luciano F Drager.
来源: Chest. 2016年149卷6期1360-1页

358. Adjuvant Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Yes, No, Maybe So?

作者: Mellar P Davis.;Vamsidhar Velcheti.;Nathan A Pennell.
来源: Chest. 2016年149卷6期1357-9页

359. To Sleep, Perhaps to Dream: Sedatives and the Uncertainties Surrounding Therapeutic Choices in Critical Care.

作者: Yoanna Skrobik.
来源: Chest. 2016年149卷6期1355-6页

360. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.

作者: Hossein-Ardeschir Ghofrani.;Marc Humbert.;David Langleben.;Ralph Schermuly.;Johannes-Peter Stasch.;Martin R Wilkins.;James R Klinger.
来源: Chest. 2017年151卷2期468-480页

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary vasculature, leading to elevated pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR). If untreated, they can result in death due to right-sided heart failure. Riociguat is a novel soluble guanylate cyclase (sGC) stimulator that is approved for the treatment of PAH and CTEPH. We describe in detail the role of the nitric oxide-sGC-cyclic guanosine monophosphate (cGMP) signaling pathway in the pathogenesis of PAH and CTEPH and the mode of action of riociguat. We also review the preclinical data associated with the development of riociguat, along with the efficacy and safety data of riociguat from initial clinical trials and pivotal phase III randomized clinical trials in PAH and CTEPH.

结果排序

文献格式

出版时间

出版类型

出版语言